dr. patel on cediranib versus olaparib in recurrent platinum-sensitive ovarian cancer
Published 9 years ago • 184 plays • Length 2:13Download video MP4
Download video MP3
Similar videos
-
2:12
dr. patel on an analysis of olaparib and cediranib for ovarian cancer
-
0:55
a study of olaparib and cediranib in ovarian cancer
-
1:38
dr. liu on cediranib/olaparib in recurrent ovarian cancer
-
0:53
dr. annunziata on olaparib and cediranib combination in ovarian cancer
-
4:52
cediranib plus olaparib significantly increases pfs in recurrent ovarian cancer
-
4:19
cediranib plus olaparib increases progression-free survival in recurrent ovarian cancer
-
0:54
dr. ursula matulonis on phase iii trials examining cediranib plus olaparib in ovarian cancer
-
1:29
significant factors of clinical outcomes with olaparib in patients with ovarian cancer
-
2:48
rationale for olaparib in advanced ovarian cancer
-
6:51
platinum sensitivity and parp inhibition in ovarian cancer
-
11:22
olaparib in ovarian cancer
-
1:48
dr. penson on olaparib monotherapy vs chemo for ovarian cancer
-
1:25
olaparib in ovarian cancer
-
1:20
dr. ledermann discusses olaparib in ovarian cancer
-
4:25
gynecologic oncology at esmo congress 2021: randomised phase ii trial of olaparib
-
1:54
dr. matulonis on toxicities with olaparib for patients with ovarian cancer
-
28:52
gynecologic cancer education: clinical trials update
-
1:42
phase iii results for rucaparib in ovarian cancer
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer